DanBred has delivered a strong financial performance last year, underpinned by continued genetic progress and substantial growth across the international markets where it operates.
In 2025, the Danish genetics company, which has a presence in the UK, increased its revenue over €175 million, approximately 20% up on the 2024 of €147m. EBITDA (earnings before interest, taxes, depreciation and amortization) reached more than €16.1m, up €8.2m year on year, with profit before tax totalled of €13.6m, more than double the 2024 figure of €6m.
Global growth
DanBred launched its new strategy in 2025, setting out a clear direction for how it will continue its global growth in the coming years and bring its genetics closer to the customers.
The company said it has strengthened and expanded its organisation in the 18 countries where the company has its own employees, adding that ‘the strong financial results were achieved in a global market characterised by intense competition, where DanBred managed to maintain its momentum and further strengthen its market position’.
It added that its performance was also partly driven by DanBred’s ongoing genetic improvements, which deliver significantly increased productivity in Danish pig production.
Genetic progress over the past two years has contributed to an additional €5 per finisher pig, ‘clearly increasing value creation for producers’. DanBred’s targeted breeding work continues to translate genetic advances into concrete economic gains in production, it added.
Strategic execution
Truels Damsgaard, chairman of Danbred’s board, said: “The 2025 financial results reflect skilled strategic execution and strong organisational impact. DanBred has delivered solid growth while continuing to improve operational efficiency. The Board is very satisfied with this year’s results, which support our long-term ambitions.”
CEO Torben Aarris added: “2025 has been a strong year for the entire organisation. We have delivered growth in all regions while also launching several long-term initiatives to secure our continued global position. The results clearly demonstrate the added value of our product and, not least, the dedicated efforts of our employees.”